This company has been marked as potentially delisted and may not be actively trading. NYSE:AGN Allergan (AGN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Allergan Stock (NYSE:AGN) 30 days 90 days 365 days Advanced Chart Get Allergan alerts:Sign Up Key Stats Today's Range$191.64▼$193.3850-Day Range$184.04▼$193.8952-Week Range$114.27▼$202.21Volume12.44 million shsAverage Volume4.01 million shsMarket Capitalization$63.50 billionP/E RatioN/ADividend Yield1.53%Price TargetN/AConsensus RatingN/A Company Overview Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products. The company also offers breast implants and tissue expanders; and RM-131 (relamorelin), a peptide ghrelin agonist for the treatment of diabetic gastroparesis. In addition, it develops medical and cosmetic treatments; therapies for non-alcoholic steatohepatitis and other liver diseases; inhibitor for the treatment of psoriasis and other autoimmune disorders; atopic dermatitis drug candidate; peri-ocular rings for extended drug delivery and reducing elevated intraocular pressure in glaucoma patients; and treatments for neurodegenerative disorders, including Alzheimer's disease. Further, the company develops RST-001, a novel gene therapy for the treatment of retinitis pigmentosa; small molecule therapeutics for inflammatory and fibrotic diseases; topical medicines for fat reduction; and delivery system and botulinum toxin-based prescription products. It has collaboration, option, and license agreement with Lyndra, Inc.; and strategic alliance and option agreement with Editas Medicine, Inc. Allergan plc also has licensing agreements with Assembly Biosciences, Inc.; MedImmune; and Heptares Therapeutics, Ltd. The company was formerly known as Actavis plc and changed its name to Allergan plc in June 2015. Allergan plc was founded in 1983 and is headquartered in Dublin, Ireland. Read More Receive AGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allergan and its competitors with MarketBeat's FREE daily newsletter. Email Address AGN Stock News HeadlinesIncyte Shares Gain Following Appointment of New CEO Bill MeuryJune 26, 2025 | msn.comA Montreal woman is the lead plaintiff in Allergan breast implant class actionMay 24, 2025 | msn.comA new rule goes live in July — and the banks are quietly cashing inA major change is quietly going into effect this July — and Wall Street is already positioning for it. Big Banks have found a way to use a new asset as if it were cash. Not stocks. Not bonds. Not even the U.S. dollar. They now trust this asset more than the traditional financial system itself.July 14 at 2:00 AM | American Alternative (Ad)Allergan Aesthetics Boosts Women Entrepreneurs with BOTOX Cosmetic Initiative (ABBV)May 3, 2025 | gurufocus.comAlgernon Pharmaceuticals Inc.: Algernon Pharmaceuticals Receives Notice of Allowance from European Patent Office for Repirinast for Kidney DiseaseApril 8, 2025 | finanznachrichten.deAllergan Aesthetics Emphasizes Commitment to Innovation, Science and a Patient Centric Approach at AMWC 2025March 24, 2025 | prnewswire.comAllergan Aesthetics to Launch Immersive Training Centers Worldwide in Advanced Aesthetics Techniques for Health Care ProfessionalsMarch 7, 2025 | msn.comEarnings call transcript: AbbVie Q4 2024 beats expectations, shares riseFebruary 1, 2025 | msn.comSee More Headlines AGN Stock Analysis - Frequently Asked Questions How were Allergan's earnings last quarter? Allergan plc (NYSE:AGN) issued its quarterly earnings data on Monday, February, 10th. The company reported $5.22 earnings per share for the quarter, beating analysts' consensus estimates of $4.57 by $0.65. The firm's revenue for the quarter was up 6.6% compared to the same quarter last year. What other stocks do shareholders of Allergan own? Based on aggregate information from My MarketBeat watchlists, some other companies that Allergan investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Micron Technology (MU) and Aegean Marine Petroleum Network (ANW). Company Calendar Last Earnings2/10/2020Today7/14/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Pharmaceutical Preparations Sub-IndustryPharmaceuticals Current SymbolNYSE:AGN Previous SymbolNYSE:ACT CIK1578845 Webwww.allergan.com Phone862-261-7000FaxN/AEmployees17,400Year FoundedN/AProfitability EPS (Trailing Twelve Months)$17.64 Trailing P/E RatioN/A Forward P/E Ratio11.56 P/E Growth1.63Net Income-$5.27 billion Net Margins-15.44% Pretax MarginN/A Return on Equity8.46% Return on Assets5.31% Debt Debt-to-Equity Ratio0.31 Current Ratio1.01 Quick Ratio0.84 Sales & Book Value Annual Sales$16.09 billion Price / Sales3.95 Cash Flow$36.70 per share Price / Cash Flow5.26 Book Value$177.28 per share Price / Book1.09Miscellaneous Outstanding Shares329,002,000Free FloatN/AMarket Cap$63.50 billion OptionableOptionable Beta1.20 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NYSE:AGN) was last updated on 7/14/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTrump’s biggest move, misreportedThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allergan plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Allergan With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.